A Study to Evaluate the Safety, Preliminary Efficacy, and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients With Pulmonary Fibrosis or Thyroid Eye Disease

I. Participant Inclusion Criteria-

Parts A, B, C, and D

1. Female participants must be nonpregnant, nonlactating, and either postmenopausal for ≥12 months, surgically sterile for ≥6 months, or agree to use 2 effective methods ofcontraception or a highly effective method of contraception. Males must besurgically sterile for ≥6 months or agree to highly effective methods ofcontraception.

2. Able to comprehend and willing to sign an ICF and understand and comply with therequirements of the study. Part A and Part B only

3. Males or females, 18 through 60 years of age, inclusive

4. Body weight ≥110 pounds (≥50 kg); body mass index (BMI) within the range of 18through 32.0 kg/m2

5. In good health as determined by the Investigator Part C only

6. Male and female patients >40 years of age (IPF patients) or ≥21 years of age (PF-ILDpatients) IPF-specific Inclusion Criteria:

7. A diagnosis of IPF

8. IPF has been stable for ≥3 months at Screening PF-ILD-specific Inclusion Criteria:

9. Patients with physician diagnosed ILD who fulfill ≥1 of the following criteria forPF-ILD within 24 months of the Screening visit despite treatment with approvedand/or unapproved medications used in clinical practice to treat ILD.

10. Fibrosing lung disease on HRCT performed within 3 years of the Screening Visit

11. For patients with underlying CTD: stable CTD as defined by no initiation of newtherapy or withdrawal of therapy for CTD within 6 weeks before the Screening visit

12. FVC ≥45% predicted Part D only

13. Male or female patients of age ≥18 years

14. Clinical diagnosis of Graves' disease associated with active TED

15. Moderate-to-severe active TED

16. Less than 15 months from onset of TED in the study eye

17. No previous medical treatment for TED with the exception of local supportivemeasures, mycophenolate and oral or injectable steroids, immunomodulating therapies,and/or orbital irradiation/radiotherapy

II. Participant Exclusion Criteria

Parts A, B, C, and D

1. Any acute or chronic condition that would limit the participant's ability toparticipate in and complete this clinical study Part A and Part B only

2. Significant history or clinical manifestation of any significant endocrine,metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary,cardiovascular, gastrointestinal, neurological, or psychiatric disorder

3. History of significant hypersensitivity; intolerance; or allergy to any drugcompound, food, or other substance; or history of anaphylaxis or angioedema

4. Positive serum test for HIV or hepatitis infection

5. Currently receiving any antibiotics for upper or lower respiratory tract infections

6. Use of any prescription drug or vaccine within 21 days before Check-in with theexception of hormonal contraceptives and vaccines.

7. Any prescription biologic within 3 months or 5 half-lives (whichever is greater)before Check-in

8. Participation in any other investigational study drug trial in which aninvestigational study drug was administered within 30 days before randomization oran investigational biological study drug was administered within 3 months beforeCheck-in Part C only

9. History of clinically relevant cardiovascular disease that could jeopardize apatient's health during the course of the study

10. Patients with concurrent active malignancy other than adequately treated basal cellcarcinoma of the skin or carcinoma in situ of the cervix

IPF-specific Exclusion Criteria:

11. FVC <45% predicted of normal or a forced expiratory volume during the first secondof the forced breath (FEV1)/FVC ratio of <0.7

12. Extent of emphysema in the lungs exceeds fibrosis

13. Currently receiving pirfenidone or nintedanib if on treatment for <3 consecutivemonths or needed dose modification due to AEs in the last 3 months PF-ILD-specific Exclusion Criteria:

14. Diagnosis of IPF

15. Diagnosis of sarcoidosis

16. Significant pulmonary arterial hypertension

17. FVC <45% predicted of normal or a FEV1/FVC ratio of <0.7

18. Previous treatment with pirfenidone Part D only

19. Any previous use of anti-insulin-like growth factor 1 receptor monoclonal antibody (eg, teprotumumab) at any time

20. Patients with 2 mm proptosis decrease between Screening and Baseline, or a 1-pointdecrease on the CAS 7-point scale in any 2 weeks during the Screening period

21. Patients with decreased best corrected visual acuity due to optic neuropathy, newvisual field defect, or color defect secondary to optic nerve involvement within thelast 6 months before Screening